Wolfgang Miesbach: Targeted Anti-TFPI Therapy with Marstacimab Supports Joint Stability in Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Michael Sigl-Kraetzig and colleagues presented at GTH 2026 in Bonn the first European real-world experience with Marstacimab in a patient with haemophilia A and advanced haemophilic arthropathy.
The poster describes a switch from intravenous factor prophylaxis to subcutaneous anti-TFPI prophylaxis (Marstacimab) in a patient with poor prior adherence, resulting in a lower treatment burden and markedly improved adherence.
Joint status was monitored clinically and by standardised ultrasound (HEAD-US), enabling structured assessment of arthropathy progression.
Following a post-traumatic bleed, treatment was escalated to a doubled Marstacimab dose, with ongoing excellent adherence and no thromboembolic events reported so far.
This case highlights how targeted anti-TFPI therapy, combined with standardised imaging and individualised dose adjustment, may support adherence and help stabilise joint outcomes in haemophilia care.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 13:0810 Posts Not to Miss This Week
-
Oct 18, 2026, 12:58Pierpaolo Di Micco: DOACs vs Vitamin K Antagonists in Long-Term Anticoagulation
-
Oct 18, 2026, 12:51Arianne Missimer: Understanding Ferritin Levels Beyond the Normal Range
-
Oct 18, 2026, 12:37Roberto C. Iglesias: Colon Cancer Prevention Beyond Supplements and Vitamins
-
Oct 18, 2026, 12:27Rafael Alejandro Camero Del Vecchio: Paroxysmal Nocturnal Hemoglobinuria Advancing Complement Inhibition with Ravulizumab
-
Oct 18, 2026, 12:26Abdul Mannan: When INR Misleads – Rethinking Bleeding Risk in Cirrhosis
-
Oct 18, 2026, 12:14Stéphane Laurent: The People and Technology Behind Safe Blood Transfusion
-
Oct 18, 2026, 12:14Abhi Kapuria: When VTE Prophylaxis Breaks Down in the ICU
-
Oct 18, 2026, 11:37Lee Anne Sorto: Beyond Compliance – Making Audits Count in Transfusion Safety